Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 218 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable... January 26, 2023 ¿El azúcar provoca cáncer? September 20, 2022 Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung... May 8, 2021 Load more HOT NEWS With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... What Are Patient-Reported Outcomes and Why Are They Important in Cancer... Understanding Serving Sizes No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as...
